Sanofi SA (SNY) is having a rough stretch. The French pharmaceutical giant with a $113.6 billion market cap saw shares drop 4.5% on Thursday, landing closer to its 52-week low of $44.62 than its high of $60.12. Friday's premarket session brought more pain, with shares down another 0.68% to $46.71.
The immediate catalyst? A leadership shakeup that nobody saw coming. The board announced Thursday it won't renew CEO Paul Hudson's mandate, with his last day set for February 17. Belén Garijo will step in as the new chief executive after the company's Annual General Meeting on April 29. The board's messaging was clear: Sanofi needs enhanced strategy and innovation capacity, particularly in Research & Development.
When Your Best Drug Is Also Your Biggest Problem
Here's the paradox keeping investors up at night: Sanofi's flagship drug Dupixent is absolutely crushing it, with fourth-quarter 2025 sales jumping 32.2% to 4.2 billion euros. That's the good news. The complicated news is that Dupixent now represents roughly 30% of the company's total sales, and it will eventually lose patent exclusivity. When your blockbuster accounts for nearly a third of revenue, the pressure to develop the next big thing becomes intense.
Sanofi shares the profits from this immunology blockbuster with Regeneron Pharmaceuticals Inc. (REGN), but even a shared goldmine creates dependency issues. Meanwhile, other parts of the business are struggling. Vaccine sales declined 2.5% to 2 billion euros in the quarter, adding to concerns about whether the pipeline can pick up the slack when Dupixent's exclusivity window closes.
The Technical Picture Isn't Pretty
From a chart perspective, Sanofi is showing bearish tendencies. The stock trades 1.1% below its 20-day simple moving average and 4% below its 100-day SMA, suggesting weakness in both the short and medium term. Over the past year, shares have fallen 12.89%, positioning them much closer to 52-week lows than highs.
The momentum indicators tell a mixed story. The RSI sits at 45.73, which is neutral territory—neither oversold nor overbought. The MACD is above its signal line, indicating some bullish momentum. That combination creates uncertainty about which direction the stock heads next. Traders are watching key resistance at $49.00 and support at $45.00.
What Analysts Are Thinking
Despite the recent turbulence, Wall Street maintains a Buy rating on Sanofi with an average price target of $61.50. That implies about 32% upside from current levels, suggesting analysts believe the market is overreacting to near-term concerns. However, confidence has been slipping. Recent analyst actions paint a cautious picture:
- UBS downgraded to Neutral on January 16
- Barclays downgraded to Equal-Weight on January 6
- Guggenheim downgraded to Neutral on December 9, 2025
That's three downgrades in quick succession, which isn't exactly a vote of confidence. Still, the consensus view suggests analysts see the growth prospects as justification for the substantial upside to their targets, even with the stock trading at what they consider a fair P/E multiple.
The Bigger Picture
Sanofi's business model centers on immunology, vaccines, and rare diseases. The company offers a diverse portfolio, but Dupixent's dominance creates both opportunity and risk. The leadership change reflects the board's recognition that the company needs to strengthen its innovation engine and address pipeline challenges head-on.
For Garijo, the new CEO, the mandate is clear: find the next Dupixent before the current one loses exclusivity, stabilize the vaccine business, and restore investor confidence. No pressure. The market will be watching closely to see whether new leadership can deliver the strategic rigor the board is demanding, or whether Sanofi's best days are already behind it.
